Tower Research Capital (TRC): Arbutus Biopharma ABUS Historial de posiciones en acciones
Comprado
Mantenidas
Vendido
| Trimestre | Valor de mercado | Estado | Acciones |
Cambio en la posición | Valor operado | Peso en el portafolio | Puesto en el portafolio | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | USD 402 k | Compra |
84,186
+76,467
| +991% | +USD 368 k | ﹤0.01% | 1854 |
|
|
2026
Q2 | USD 37.1 k | Venta |
7,719
-8,576
| -53% | -USD 37.7 k | ﹤0.01% | 2990 |
|
|
2026
Q1 | USD 73.3 k | Compra |
16,295
+8,288
| +104% | +USD 36.2 k | ﹤0.01% | 2431 |
|
|
2025
Q4 | USD 38.5 k | Venta |
8,007
-4,687
| -37% | -USD 21.1 k | ﹤0.01% | 2626 |
|
|
2025
Q3 | USD 57.6 k | Venta |
12,694
-8,066
| -39% | -USD 29.6 k | ﹤0.01% | 2417 |
|
|
2025
Q2 | USD 64.1 k | Compra |
20,760
+14,275
| +220% | +USD 47.4 k | ﹤0.01% | 2753 |
|
|
2025
Q1 | USD 22.6 k | Venta |
6,485
-6,294
| -49% | -USD 21 k | ﹤0.01% | 2841 |
|
|
2024
Q4 | USD 41.8 k | Compra |
12,779
+1,900
| +17% | +USD 6.99 k | ﹤0.01% | 2668 |
|
|
2024
Q3 | USD 41.9 k | Venta |
10,879
-5,454
| -33% | -USD 20.9 k | ﹤0.01% | 2818 |
|
|
2024
Q2 | USD 50.5 k | Compra |
16,333
+14,474
| +779% | +USD 43.4 k | ﹤0.01% | 3094 |
|
|
2024
Q1 | USD 4.8 k | Venta |
1,859
-4,396
| -70% | -USD 11.4 k | ﹤0.01% | 4626 |
|
|
2023
Q4 | USD 15.6 k | Venta |
6,255
-3,254
| -34% | -USD 6.37 k | ﹤0.01% | 3816 |
|
|
2023
Q3 | USD 19.3 k | Compra |
9,509
+2,397
| +34% | +USD 5.02 k | ﹤0.01% | 3411 |
|
|
2023
Q2 | USD 16.4 k | Venta |
7,112
-2,680
| -27% | -USD 6.98 k | ﹤0.01% | 3565 |
|
|
2023
Q1 | USD 30 k | Venta |
9,792
-5,026
| -34% | -USD 14.2 k | ﹤0.01% | 2980 |
|
|
2022
Q4 | USD 35 k | Compra |
14,818
+4,170
| +39% | +USD 10 k | ﹤0.01% | 2600 |
|
|
2022
Q3 | USD 21 k | Venta |
10,648
-5,375
| -34% | -USD 12.7 k | ﹤0.01% | 3879 |
|
|
2022
Q2 | USD 43 k | Compra |
16,023
+5,450
| +52% | +USD 13.9 k | ﹤0.01% | 3030 |
|
|
2022
Q1 | USD 31 k | Compra |
10,573
+5,963
| +129% | +USD 18.3 k | ﹤0.01% | 3100 |
|
|
2021
Q4 | USD 17 k | Venta |
4,610
-1,152
| -20% | -USD 4.48 k | ﹤0.01% | 3826 |
|
|
2021
Q3 | USD 25 k | Venta |
5,762
-2,844
| -33% | -USD 9.48 k | ﹤0.01% | 3508 |
|
|
2021
Q2 | USD 26 k | Compra |
8,606
+4,158
| +93% | +USD 12.9 k | ﹤0.01% | 3631 |
|
|
2021
Q1 | USD 15 k | Venta |
4,448
-130
| -3% | -USD 502 | ﹤0.01% | 4088 |
|
|
2020
Q4 | USD 16 k | Compra |
4,578
+175
| +4% | +USD 613 | ﹤0.01% | 3994 |
|
|
2020
Q3 | USD 14 k | Venta |
4,403
-6,941
| -61% | -USD 21.1 k | ﹤0.01% | 3954 |
|
|
2020
Q2 | USD 21 k | Venta |
11,344
-899
| -7% | -USD 1.47 k | ﹤0.01% | 3644 |
|
|
2020
Q1 | USD 12 k | Compra |
12,243
+12,143
| +12,143% | +USD 32.8 k | ﹤0.01% | 1927 |
|
|
2019
Q4 | USD 0 | Venta |
100
-38,689
| -100% | -USD 62.6 k | ﹤0.01% | 3438 |
|
|
2019
Q3 | USD 59 k | Compra |
38,789
+34,005
| +711% | +USD 58.6 k | ﹤0.01% | 1669 |
|
|
2019
Q2 | USD 10 k | Venta |
4,784
-2,861
| -37% | -USD 7.32 k | ﹤0.01% | 2540 |
|
|
2019
Q1 | USD 28 k | Venta |
7,645
-2,564
| -25% | -USD 9.8 k | ﹤0.01% | 2079 |
|
|
2018
Q4 | USD 39 k | Compra |
10,209
+8,647
| +554% | +USD 42.6 k | ﹤0.01% | 1446 |
|
|
2018
Q3 | USD 15 k | Compra |
1,562
+850
| +119% | +USD 8.44 k | ﹤0.01% | 2511 |
|
|
2018
Q2 | USD 5 k | Venta |
712
-1,836
| -72% | -USD 10.9 k | ﹤0.01% | 3045 |
|
|
2018
Q1 | USD 13 k | Compra |
+2,548
| Nuevas | +USD 13.5 k | ﹤0.01% | 2349 |
|
|
2017
Q4 | – | Venta |
-8,283
| Cerradas | -USD 51 k | – | 3447 |
|
|
2017
Q3 | USD 51 k | Venta |
8,283
-1,943
| -19% | -USD 8.31 k | ﹤0.01% | 1947 |
|
|
2017
Q2 | USD 37 k | Compra |
10,226
+5,377
| +111% | +USD 18.5 k | ﹤0.01% | 897 |
|
|
2017
Q1 | USD 16 k | Venta |
4,849
-3,803
| -44% | -USD 10.6 k | ﹤0.01% | 1420 |
|
|
2016
Q4 | USD 21 k | Compra |
8,652
+7,180
| +488% | +USD 20.9 k | ﹤0.01% | 2076 |
|
|
2016
Q3 | USD 5 k | Venta |
1,472
-810
| -35% | -USD 3.16 k | ﹤0.01% | 2516 |
|
|
2016
Q2 | USD 8 k | Venta |
2,282
-3,913
| -63% | -USD 16.6 k | ﹤0.01% | 2998 |
|
|
2016
Q1 | USD 25 k | Venta |
6,195
-1,471
| -19% | -USD 5.26 k | ﹤0.01% | 1179 |
|
|
2015
Q4 | USD 35 k | Compra |
7,666
+2,366
| +45% | +USD 13 k | 0.01% | 758 |
|
|
2015
Q3 | USD 32 k | Sin cambios |
5,300
| – | – | ﹤0.01% | 1331 |
|
|
2015
Q2 | USD 63 k | Venta |
5,300
-12
| -0.2% | -USD 183 | 0.01% | 1183 |
|
|
2015
Q1 | USD 93 k | Compra |
5,312
+4,500
| +554% | +USD 92.2 k | 0.01% | 957 |
|
|
2014
Q4 | USD 12 k | Compra |
812
+621
| +325% | +USD 10.7 k | ﹤0.01% | 1965 |
|
|
2014
Q3 | USD 4 k | Venta |
191
-546
| -74% | -USD 8.92 k | ﹤0.01% | 3395 |
|
|
2014
Q2 | USD 10 k | Venta |
737
-95
| -11% | -USD 1.35 k | ﹤0.01% | 2337 |
|
|
2014
Q1 | USD 18 k | Venta |
832
-3,084
| -79% | -USD 55.4 k | ﹤0.01% | 1981 |
|
|
2013
Q4 | USD 31 k | Compra |
3,916
+2,631
| +205% | +USD 21.9 k | 0.01% | 1839 |
|
|
2013
Q3 | USD 9 k | Compra |
+1,285
| Nuevas | +USD 7.08 k | ﹤0.01% | 3258 |
|
Otros fondos que tienen ABUS en su portafolio
Posición de Tower Research Capital (TRC) en ABUS: resumen de T3 2026
Tower Research Capital (TRC) aumentó su participación en Arbutus Biopharma (ABUS) en 991% durante T3 2026, al comprar aproximadamente USD 368 k y elevar la posición a 84,186 acciones con un valor de USD 402 k. La posición representa ﹤0.01% del portafolio y ocupa el puesto #1854.
Tower Research Capital (TRC) reportó por primera vez una posición en ABUS en T3 2013 y desde entonces la ha mantenido en 52 trimestres. Al cierre de T3 2026, 216 fondos que sigue Wall St. Rank mantienen una posición en ABUS.
- Al cierre de T3 2026, Tower Research Capital (TRC) tenía 84,186 acciones de Arbutus Biopharma con un valor de USD 402 k.
- Tower Research Capital (TRC) compró 76,467 acciones de Arbutus Biopharma en T3 2026, por un monto estimado de USD 368 k.
- Arbutus Biopharma representó el ﹤0.01% del portafolio de Tower Research Capital (TRC) en T3 2026 y fue su posición número 1854.
- Tower Research Capital (TRC) reportó por primera vez una posición en Arbutus Biopharma en T3 2013 y desde entonces la ha mantenido en 52 trimestres.
- Al cierre de T3 2026, 216 fondos que sigue Wall St. Rank tenían Arbutus Biopharma en su portafolio.
Según el informe 13F de Tower Research Capital (TRC) correspondiente a T3 2026, presentado el 16 nov 2026.